The total amount of US-based Halda Therapeutics’ series B investment round reached $ 202 million.
Halda Therapeutics, which focuses on cancer treatment, received an investment of $ 126 million. The total amount of the company’s B series investment round reached $ 202 million.
US-based Halda Therapeutics’ investment round included Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, Taiho Ventures, Canaan Partners, Access Biotechnology, Elm Street Ventures and Connecticut Innovations.
The company announced that it will use the new investment to initiate clinical trials of two new drugs for the treatment of prostate and breast cancer.
Halda Therapeutics is defined as a technology company focused on developing innovative solutions for cancer treatment. The company is working on a new cancer treatment method called RIPTA, Regulated Induced Proximity Targeting Chimeras.
RIPTAC therapies use a catch-and-kill mechanism to target and kill cancer cells. This method aims to overcome the resistance that cancer cells develop against existing drugs. On the one hand, existing cancer drugs can become ineffective due to the development of resistance by cells. RIPTAC technology aims to overcome this resistance and provide a more effective treatment.
Halda Therapeutics is working on solid tumours that are difficult to treat, such as prostate and breast cancer. These types of cancer are often resistant to standard treatments and can be difficult to treat. The company plans to launch two main drugs developed with RIPTAC technology into clinical trials.
